Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency

被引:39
|
作者
Mechler, Konstantin [1 ]
Mountford, William K. [2 ]
Hoffmann, Georg F. [3 ]
Ries, Markus [3 ]
机构
[1] Heidelberg Univ, Pediat Psychopharmacol, Dept Child & Adolescent Psychiat & Psychotherapy, Cent Inst Mental Hlth,Med Fac Mannheim, Mannheim, Germany
[2] Univ N Carolina, Dept Clin Res, Sch Nursing, Coll Hlth & Human Serv, Wilmington, NC 28401 USA
[3] Univ Heidelberg Hosp, Pediat Neurol & Ctr Rare Disorders, Ctr Pediat & Adolescent Med, Heidelberg, Germany
关键词
drug development; molybdenum cofactor deficiency; natural history; orphan disease; survival; THERAPY;
D O I
10.1038/gim.2015.12
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Experimental treatment with substrate replacement was successfully performed in single cases with molybdenum cofactor deficiency type A. The objective of this study was to quantitate the yet undefined natural history in untreated patients to ultimately benefit knowledge in experimental treatments in the future. Methods: Systematic analysis of published cases with molybdenum cofactor deficiency. The main outcome measures were survival, initial cardinal disease features at onset, and diagnostic delay. Results: The median survival for the overall population was 36 months. Initial cardinal disease features at onset were seizures (72%) as well as feeding difficulties (26%) and hypotonia (11%). In addition, developmental delay (9%), hemiplegia (2%), lens dislocation (2%), and hyperreflexia (1%) were reported. The median age at onset of the disease was the first day of life; the median age at diagnosis was 4.5 months. The median time to diagnosis (diagnostic delay) was 89 days. Conclusion: Molybdenum cofactor deficiency has its onset during the neonatal period and infancy. There is considerable diagnostic delay. Although seizures were the most frequent initial cardinal sign, molybdenum cofactor deficiency should be considered as a differential diagnosis in patients presenting with hypotonia, developmental delay, or feeding difficulties. The survival data will inform further natural-history and therapeutic studies.
引用
收藏
页码:965 / 970
页数:6
相关论文
共 40 条
  • [1] Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis
    Zielonka, Matthias
    Garbade, Sven F.
    Koelker, Stefan
    Hoffmann, Georg F.
    Ries, Markus
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2019, 42 (05) : 975 - 983
  • [2] Molybdenum cofactor deficiency: A natural history
    Spiegel, Ronen
    Schwahn, Bernd C.
    Squires, Liza
    Confer, Nils
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2022, 45 (03) : 456 - 469
  • [3] PATIENT VOICE IN SMC TECHNOLOGY APPRAISALS FOR ORPHAN AND ULTRA-ORPHAN DISEASES
    Gupta, A.
    Jindal, S.
    Mahajan, K.
    Sharma, A.
    Saharia, P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S486 - S486
  • [4] A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features
    Zielonka, Matthias
    Garbade, Sven F.
    Kolker, Stefan
    Hoffmann, Georg F.
    Ries, Markus
    [J]. GENETICS IN MEDICINE, 2018, 20 (05) : 524 - 530
  • [5] Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
    Schlander, Michael
    Adarkwah, Charles Christian
    Gandjour, Afschin
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (01) : 171 - 179
  • [6] A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder
    Zielonka, Matthias
    Garbade, Sven F.
    Koelker, Stefan
    Hoffmann, Georg F.
    Ries, Markus
    [J]. GENETICS IN MEDICINE, 2019, 21 (02) : 347 - 352
  • [7] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [8] Treatments for rare diseases: molybdenum cofactor deficiency
    Wilcken, Bridget
    [J]. LANCET, 2015, 386 (10007): : 1924 - 1925
  • [9] THE NEW SMC ULTRA-ORPHAN PATHWAY: HTA BEST PRACTICE FOR VERY RARE DISEASES?
    Carr, D.
    Macaulay, R.
    [J]. VALUE IN HEALTH, 2021, 24 : S241 - S241
  • [10] ANALYSIS OF THE ULTRA-ORPHAN DRUGS APPROVED BY THE FDA IN THE PERIOD 1983-2014
    Thumar, R.
    Seoane-Vazquez, E.
    Mantus, D.
    Tyrrell, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A255 - A255